RESEARCH - Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies

[Guest guest]

Curr Opin Investig Drugs. 2008 Nov;9(11):1206-15.

Ocrelizumab, a humanized monoclonal antibody against CD20 for

inflammatory disorders and B-cell malignancies.

Hutas G.

Semmelweis University, Department of Rheumatology, Polyclinic of the

Hospitaller Brothers of St of God, Budapest, Hungary.

Biogen Idec Inc, Genentech Inc, Roche Holding AG and Chugai

Pharmaceutical Co Ltd are developing ocrelizumab, a humanized mAb

against CD20, for the potential treatment of inflammatory disorders

and B-cell malignancies. Ocrelizumab is undergoing phase III clinical

trials for rheumatoid arthritis and lupus nephritis, and phase II

trials for multiple sclerosis and hematological cancer. Previously,

ocrelizumab was also being developed for the treatment of systemic

lupus erythematosus (SLE) and neuromyelitis optica; however,

development for SLE has been discontinued. No development has been

reported for neuromyelitis optica and as of January 2007, this

indication had been removed from the company pipeline.

PMID: 18951300

http://www.ncbi.nlm.nih.gov/pubmed/18951300

Not an MD